Mazor Robotics Receives First Order for Renaissance System with Brain Module
U.S. Based Hospital Will Use Renaissance System for Spine and Brain Procedures
CAESAREA, Israel--(BUSINESS WIRE)--Mazor Robotics Ltd., a developer of innovative guidance systems and complementary products, announced today that it has received the first order for its Renaissance system since the commercial launch of the brain surgery module.
“The first order for Renaissance with our brain surgery module is a new milestone for Mazor Robotics. The value proposition offered to our customers enabled our team to achieve the first system placement in the U.S., less than three months after we commercially launched the brain application”
The system was sold to Bryan Medical Center in Lincoln, NE and will be utilized for spine and brain procedures. Bryan Medical Center is a 640-bed, not-for-profit, locally owned and governed health care organization serving patients from throughout Nebraska, as well as parts of Kansas, Iowa, South Dakota and other states in the region.
“The first order for Renaissance with our brain surgery module is a new milestone for Mazor Robotics. The value proposition offered to our customers enabled our team to achieve the first system placement in the U.S., less than three months after we commercially launched the brain application,” commented Ori Hadomi, Chief Executive Officer. “The versatility of the Renaissance system enables surgeons and hospital administrators to deploy a single proven system for both brain and spine procedures.”
The Company commercially launched the brain application at the American Association of Neurological Surgeons (AANS) annual meeting in April 2014. Renaissance’s brain module is primarily used to assist with Deep Brain Stimulation (DBS) procedures to treat movement disorders, such as Parkinson’s disease. Three other hospitals, including Littleton Adventist (Littleton, CO), were utilizing the brain application during a pre-launch testing period and continue to use the system for brain surgeries.
Mazor Robotics is dedicated to the development and marketing of innovative surgical guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance®, is a state-of-the-art surgical guidance system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 45,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding Mazor Robotics’ belief that the first order of its Renaissance system with the brain surgery module is a milestone, and that the versatility of the Renaissance system enables surgeons and hospital administrators to deploy a single proven system for both brain and spine procedures, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor’s annual report on Form 20-F filed with the SEC on April 9, 2014 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.